Although we have comprehensively analyzed the clinical activity of the currently approved EGFR TKIs for the specific EGFR ex20ins variants A763_Y764insFQEA and D770delinsGY in advanced NSCLC patients and provided evidence from structural and molecular dynamics simulation, several limitations must be noted. Here, EGFR is linked to non-small cell lung carcinoma.